ArticleDisease markers2020
Serum Small Proline-Rich Protein 2A (SPRR2A) Is a Noninvasive Biomarker in Gastric Cancer.
Article in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Multi-omics analysis identified SPRR2D as a potential biomarker for tumor prognosis and immune microenvironment infiltration: a pan-cancer perspective.Future science OA · 2026Article
- Proteomic analysis of saliva reveals changes in proteomic profiles during colorectal cancer in an Iranian cohort.Frontiers in oncology · 2026Article
- Analysis of Selected Small Proline-Rich Proteins in Tissue Homogenates from Samples of Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Advances in carcinoembryonic antigen detection: a review of clinical applications and standardization.Analytical and bioanalytical chemistry · 2025Review
- Protein Biomarkers of Gastric Preneoplasia and Cancer Lesions in Blood: A Comprehensive Review.Cancers · 2024Review
- Article
- Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer.Frontiers in medicine · 2023Article
- Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer.Frontiers in oncology · 2023Article
- Biomarkers of gastric cancer: current advancement.Heliyon · 2022Review
- Single-cell transcriptomic analysis reveals the critical molecular pattern of UV-induced cutaneous squamous cell carcinoma.Cell death & disease · 2021Article
- Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSince early diagnosis is very important for treating gastric cancer (GC), we aimed to detect serum small proline-rich protein2A (SPRR2A) to verify its diagnostic value for GC patients.
methodsSerum samples were collected from 200 patients with GC, 100 patients with gastritis, 40 patients with rectal cancer (RC), 50 patients with colon cancer (CC), and 100 healthy controls. An enzyme-linked immunosorbent assay (ELISA) detection kit was applied to measure serum SPRR2A concentration. The correlations between serum SPRR2A and carcinoembryonic antigen (CEA), clinical pathological parameters of GC, and receiver operating characteristic (ROC) curve were also analyzed.
resultsThe median serum SPRR2A concentration in GC patients was significantly higher than those in healthy controls and gastritis or colorectal cancer patients (
conclusionThese results suggest that serum SPRR2A can be used as an effective marker for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.